It is broadly estimated that JAKs are likely to dominate around 24% of the market which is not a good news for products like Enbrel manufactured by Amgen. It is likely that the drug is to cascade into fast decline as physicians increasingly prefer JAK as a second drug after Humira of AbbVie.
Positive news that holds hope for the medical fraternity and patients is the urging by UK Prime Minister, Theresa May, for the adoption of artificial intelligence by the NHS and technology companies to diagnose critical diseases such as cancer.
The global ultrasounds systems marker is expected to clock a market value in excess of over USD 12,500 million by the end of 2028, recording a CAGR of 5.7% in the forecast period as per findings of global forecasts stated in the report titled 'Ultrasound Systems Market - Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028'.
A mobile health app developed by Medici is used by Kim who has stated that the technology helps him make the right connect with patients. He can log on to his smartphone or iPad when at home and make a HIPAA-compliant connection with concerned persons impacted by crisis or who would turn to medication.
The implementation of privacy protocols and security controls is pertinent to protecting patient records and sensitive data. However, the threat to patient safety, the core of every modern health system, being compromised is growing rapidly owing to network-connected medical devices.
As a new, erratic administration consolidated its position in the White House and firmed its foundations in the federal government, 2017 turned out to be uncertain for the biopharma industry. Then President-elect Donald Trump saying that the industry was getting away with murder on pricing did not bode well for the industry but more than a year later after the President assuming office, real reform has been spared for biopharma.
As America’s population ages, a 4 billion USD opportunity is being foreseen by Thomas DeRosa for changing the U.S. health infrastructure through instituting a low-cost healthcare network and disrupting conventional healthcare practices.
Ascletis Pharma has become the first company to seek to list (PDF) in Hong Kong under the exchange’s new, more relaxed rules on biotech IPOs. The antiviral disease specialist will use the cash to win approvals for hepatitis C drugs licensed from Roche and Presidio Pharmaceuticals.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.